Fred D. Lublin
See the following -
Transparency Life Sciences Awarded $1.4 Million NCATS SBIR Grant To Conduct Innovative Trial Of Lisinopril In Multiple Sclerosis
Press Release |
Transparency Life Sciences |
September 8, 2014
Transparency Life Sciences, LLC (TLS)...today announced that it has received a Small Business Innovation Research (SBIR) program grant to fund a Phase 2a proof-of-concept study testing the utility of the ACE inhibitor lisinopril as an adjunctive therapy for multiple sclerosis (MS).
- Login to post comments